KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Emergent BioSolutions (EBS) Deferred Taxes: 2009-2024

Historic Deferred Taxes for Emergent BioSolutions (EBS) over the last 16 years, with Dec 2024 value amounting to -$5.5 million.

  • Emergent BioSolutions' Deferred Taxes fell 239.73% to -$10.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$5.9 million, marking a year-over-year increase of 42.72%. This contributed to the annual value of -$5.5 million for FY2024, which is 38.20% up from last year.
  • According to the latest figures from FY2024, Emergent BioSolutions' Deferred Taxes is -$5.5 million, which was up 38.20% from -$8.9 million recorded in FY2023.
  • In the past 5 years, Emergent BioSolutions' Deferred Taxes registered a high of $46.0 million during FY2021, and its lowest value of -$28.6 million during FY2022.
  • Its 3-year average for Deferred Taxes is -$14.3 million, with a median of -$8.9 million in 2023.
  • Its Deferred Taxes has fluctuated over the past 5 years, first tumbled by 200.00% in 2020, then surged by 1,493.94% in 2021.
  • Over the past 5 years, Emergent BioSolutions' Deferred Taxes (Yearly) stood at -$3.3 million in 2020, then skyrocketed by 1,493.94% to $46.0 million in 2021, then crashed by 162.17% to -$28.6 million in 2022, then skyrocketed by 68.88% to -$8.9 million in 2023, then surged by 38.20% to -$5.5 million in 2024.